Patents by Inventor Maximiliano Vasquez

Maximiliano Vasquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating thrombotic diseases with von Willebrand factor specific antibodies
    Patent number: 6613328
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Grant
    Filed: January 24, 2001
    Date of Patent: September 2, 2003
    Assignee: Ajinomoto Co., Inc.
    Inventors: Man Sung Co, Maximiliano Vasquez
  • ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND FACTOR MONOCLONAL ANTIBODY
    Publication number: 20030064068
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Application
    Filed: January 24, 2001
    Publication date: April 3, 2003
    Applicant: Ajinomoto Co., Inc.
    Inventors: Man Sung Co, Maximiliano Vasquez
  • HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT THEREWITH
    Publication number: 20020176855
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: February 12, 1999
    Publication date: November 28, 2002
    Inventors: MAN SUNG CO, MAXIMILIANO VASQUEZ, BEATRIZ CARRENO, ABBIE CHERYL CELNIKER, MARY COLLINS, SAMUEL GOLDMAN, GARY S. GRAY, ANDREA KNIGHT, DENISE O'HARA, BONITA RUP, GEERTRUIDA M. VELDMAN
  • Humanized antibodies to gamma-interferon
    Publication number: 20020091240
    Abstract: The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
    Type: Application
    Filed: November 13, 2001
    Publication date: July 11, 2002
    Applicant: Protein Design Labs, Inc.
    Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
  • Humanized antibodies to &ggr;-interferon
    Patent number: 6329511
    Abstract: The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: December 11, 2001
    Assignee: Protein Design Labs, Inc.
    Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
  • Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
    Patent number: 6228360
    Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
    Type: Grant
    Filed: August 19, 1998
    Date of Patent: May 8, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Man Sung Co, Maximiliano Vasquez
  • Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
    Patent number: 6114507
    Abstract: An anti-Fas ligand antibody capable of suppressing Fas ligand-induced apoptosis to a high degree, especially humanized antibodies having less antigenecity to human, and a method for assaying the Fas ligand in human body fluid utilizing such an antibody.Measurement of the Fas ligand in human body fluid would be useful for elucidation of hepatitis B, hepatitis C, HIV infections and the like, and for prediction and diagnosis of pathological conditions associated with such diseases.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: September 5, 2000
    Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
    Inventors: Kamon Shirakawa, Tomokazu Matsusue, Shigekazu Nagata, Man Sung Co, Maximiliano Vasquez
  • Agent for suppressing a reduction of CD4.sup.+ lymphocytes
    Patent number: 6096312
    Abstract: An agent for preventing or treating AIDS which contains as its effective component an anti-Fas ligand antibody, and the method for preventing and treating AIDS by using such drug.
    Type: Grant
    Filed: January 22, 1998
    Date of Patent: August 1, 2000
    Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
    Inventors: Norio Nakamura, Kamon Shirakawa, Tomokazu Matsusue, Shigekazu Nagata, Man Sung Co, Maximiliano Vasquez
  • FAS ligand fusion proteins and their uses
    Patent number: 6046310
    Abstract: Fas ligand fusion proteins comprising a polypeptide capable of specifically binding an antigen or a cell surface marker are prepared employing recombinant DNA technology for use in, e.g., treatment of autoimmune disorders.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: April 4, 2000
    Assignee: Protein Design Labs., Inc.
    Inventors: Cary L. Queen, William P. Schneider, Maximiliano Vasquez